Novel therapies for glaucoma: a patent review 2007 – 2011

Bibliography

• Quigley HA. Glaucoma. Lancet 2011;377:1367-77
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worlwide in 2010 and 2020. Br J Ophthalmol 2006;90:151-6
   Web of Science ®Google Scholar
• Mincione F, Menabuoni L, Supuran CT. Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase – Its Inhibitors and Activators. CRC Press; Boca Raton (FL): 2004. p. 243-54
   Google Scholar
• Mincione F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors as ophthalomologic drugs. In: Supuran CT, Winum JY, editors. Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. Wiley; Hoboken: 2009. p. 139-54
   Google Scholar
• Friedenwald JS. The formation of the intraocular fluid. Am J Ophthalmol 1949;32:9-27
   PubMed Web of Science ®Google Scholar
• Kinsey VE. Comparative chemistry of of aqueous humor in posterior and anterior chambers of rabbit eye. Arch Ophthalmol 1953;50:401-17
   PubMed Web of Science ®Google Scholar
• Kinsey VE, Barany E. The rate flow of aqueous humor. II. Derivation of rate of flow and its physiologic significance. Am J Ophthalmol 1949;32:189-202
   PubMed Web of Science ®Google Scholar
• Wistrand PJ. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand 1951;24:144-8
   Google Scholar
• Becker B. The mechanism of the fall in intraocular pressure by the carbonic anhydrase inhibitor Diamox. Am J Ophthalmol 1955;39:177-83
   PubMed Web of Science ®Google Scholar
• Kinsey VE, Reddy DVN. Turnover of total carbon dioxide in aqueous humors and the effect thereon of acetazolamide. Arch Ophthalmol 1959;62:78-83
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2000;10:575-600
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 2010;16:3233-45
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
   PubMed Web of Science ®Google Scholar
• Steele RM, Batugo MR, Benedini F, Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 2009;19:6565-70
   PubMed Web of Science ®Google Scholar
• Mincione F, Benedini F, Biondi S, Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216-21
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2011; In press
   PubMed Web of Science ®Google Scholar
• Supuran C, Benedini F, Biondi S, Ongini E. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
   Google Scholar
• Chong W, Kwan M, Nukui S. 1-[4-(sulfonyl)-phenyl]-5-benzyl-1H, 1,2,4-triazole derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension. WO075152; 2008
   Google Scholar
• Sinha S, Bhat SS, Heidelbaugh TM, Heterocyclic substituted fused carbocycles useful in the treatment of conditions such as glaucoma. WO023758; 2009
   Google Scholar
• Ruckmick S, Cain R, Abreo MJ, Novel compounds and their use related to compositions for treating glaucoma and/or ocular hypertension. WO050615; 2007
   Google Scholar
• McIntire GL, Davio SR, Harms AE, Hongna W. Complexes comprising alpha-2-adrenergic receptor agonists and methods of providing neuroprotection or treating or inhibiting progression of glaucoma. US0183946; 2011
   Google Scholar
• Chiroli V, Batugo MR, Biondi S, Synthesis of nove nitric oxide (NO) – releasing esters of timolol. Bioorg Med Chem Lett 2009;19:2785-8
   PubMed Web of Science ®Google Scholar
• Old DW. Pyrrolidinones for thee treatment of glaucoma and ocular hypertension. WO005176; 2007
   Google Scholar
• Burk RM. Novel sulfonamides. WO024611; 2007
   Google Scholar
• Woodward DF, Chen J. EP2 receptor agonists for treating glaucoma. WO027468; 2007
   Google Scholar
• Prasanna G, Bosworth CF, La Fontaine JA. EP2 agonists. WO015517; 2008
   Google Scholar
• Holoboski M, Burk RM, Posner MF. Therapeutic compounds. WO073752; 2008
   Google Scholar
• Old DW. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure. WO144623; 2008
   Google Scholar
• Dinh DT, Old DW, Burk RM. Therapeutic beta-lactams. WO091764; 2009
   Google Scholar
• Maxey KM, Stanton ML. Internal 1,15-lactones of fluprostenol and related prostaglandin F2A analogs and their use in the treatment of glaucoma and intraocular hypertension. US0146821; 2008
   Google Scholar
• Woodward DF, Burk RM. Novel prostamides for the treatment of glaucoma and related diseases. US0112058; 2007
   Google Scholar
• Bakhit PG, Graham R, Olejnik O. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia. US0244051; 2007
   Google Scholar
• Johnson BA, Old DW, Donde Y, Burk RM. Therapeutic compounds. US0186885; 2009
   Google Scholar
• Reunamaki T, Pellinen P, Oksala O, Lehmussaari K. Method and composition for treating ocular hypertension and glaucoma. US0152264; 2011
   Google Scholar
• Hellberg MR, Namil A, Feng Z, Ward J. Phenylethylamine analogs and their use for treating glaucoma. WO038372; 2007
   Google Scholar
• Dantanarayana AP, May JA. Substituted furo[2,3-G]indazoles for the tretment of glaucoma. US0012291; 2009
   Google Scholar
• Mohapatra S, Hellberg MR, Feng Z. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma. WO149728; 2007
   Google Scholar
• Wax MB, Pang IH, Shepard A. Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma. WO090134; 2007
   Google Scholar
• Fleenor DL, Pang IH, Shepard A, Clark AF. Inhibitors of protein kinase C-delta for the treatment of glaucoma. WO079980; 2008
   Google Scholar
• Chen HH, Rusinko A, Hellberg MR, 6-Aminoimidazo[1,2-B]pyridazine analogs as rho kinase inhibitors for the treatment of glaucoma and ocular hypertension. WO079880; 2008
   Google Scholar
• Hellberg MR, Sharif NA. May JA, et al. (Indazol-5-yl)pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions. US0149548; 2007
   Google Scholar
• Hidaka H, Nishio M, Sumi K. Therapeutic agents for treating glaucoma. US0064681; 2008
   Google Scholar
• Hellberg MR, Rusinko A, Henderson AJ, Aminoipyrazine anlogs for treating glaucoma and other rho kinase-mediated diseases and conditions. US0216777; 2010
   Google Scholar
• Fleenor DL, Pang IH. Use of inhibitors of Jun N-terminal kinases to treat glaucoma. US0311716; 2010
   Google Scholar
• Lipton SA. Compounds that inhibit caspase activity for treating glaucoma. US0218121; 2007
   Google Scholar
• Wang WH, McNatt LG, Clarck AF, Klimko PG. Superoxide dismutase-2 expression and modulation for glaucoma diagnosis and therapy. US0085878; 2008
   Google Scholar
• Bartels SP. Selective inhibition of histone deacetylase 6 for ocular neuroprotection or for treatment or control of glaucoma. US0136024; 2010
   Google Scholar
• Shepard AR, Fleenor DL. Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma. US0120851; 2010
   Google Scholar
• Hellberg MR, Clark AF, Pang IH, Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma. US0312390; 2009
   Google Scholar
• Sharif NA. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma. US0009322; 2011
   Google Scholar
• Chatterton JE, Clark AF, Bingaman DP, RNAi-related inhibition of TNFalpha signaling pathway for treatment of glaucoma. US0135579; 2011
   Google Scholar
• Clark AF, Wang WH, McNatt L. RNAi inhibition of serum amyloid A for treatment of glaucoma. US0054008; 2011
   Google Scholar
• Clark AF, Fingert J, McNatt L, Diagnostics and therapeutics for glaucoma. US0226425; 2009
   Google Scholar
• Clark AF, Wang WH, McNatt L. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents. US0036371; 2009
   Google Scholar
• Clark AF, Wordinger RJ. Bone morphogenesis protein (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma. US0204086; 2010
   Google Scholar
• Loge C, Wallez V, Scalbert E, Rho- kinase inhibitors: Pharmacomodulation on the lead compound Y-32885. J Enzyme Inhib Med Chem 2002;17:381-90
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H, Inatani M, Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;119:1171-8
   Google Scholar
• Fang X, Yin Y, Chen YT, Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem 2010;53:5727-37
   PubMed Web of Science ®Google Scholar
• Finn P. Histone deacetylase inhibitors. In: Supuran CT, Winum JY, editors. Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. Wiley; Hoboken: 2009. p. 859-80
   Google Scholar
• Schlitzer M, Ortmann R, Altenkamper M. CaaX-protein prenyltransferase inhibitors. In: Supuran CT, Winum JY, editors. Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. Wiley; Hoboken: 2009. p. 813-58
   Google Scholar
• Webb JG, Husain S, Yates PW, Crosson CE. Kinin modulation of conventional outflow facility in the bovine eye. J Ocul Pharmacol Ther 2006;22:310-16
   PubMed Web of Science ®Google Scholar
• Harrison BA, Whitlock NA, Voronkov MV, Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem 2009;52:6515-18
   PubMed Web of Science ®Google Scholar